Zacks: Brokerages Set $2.00 Price Target for Immune Pharmaceuticals Inc (IMNP)
Immune Pharmaceuticals Inc (NASDAQ:IMNP) has earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price objective of $2.00 for the company, according to Zacks. Zacks has also given Immune Pharmaceuticals an industry rank of 101 out of 255 based on the ratings given to its competitors.
Several research firms have recently weighed in on IMNP. Maxim Group downgraded shares of Immune Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 6th. ValuEngine raised shares of Immune Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Immune Pharmaceuticals (NASDAQ:IMNP) last released its quarterly earnings results on Tuesday, May 15th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.05.
Immune Pharmaceuticals Company Profile
Immune Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis.
Featured Story: Trading Strategy Methods for Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.